Background
The Systolic Blood Pressure Intervention Trial (SPRINT) recently published its primary results after the trial was stopped by the director of the National Heart, Lung, and Blood Institute. The decision to halt the trial was based on the recommendation of the trial's Data Safety and Monitoring Board that participants needed to be informed of the differential experience on the primary cardiovascular disease (CVD) outcome (composite consisting of non-fatal myocardial infarction, acute coronary syndrome requiring hospitalization, stroke, acute decompensated heart failure, or cardiovascular death) and all-cause mortality in the two arms of the study. 1 The objectives of SPRINT were to examine the effect of treating patients with elevated blood pressure (BP) to a systolic BP (SBP) target of <120 mm Hg compared with treatment to the usually recommended SBP target of <140 mm Hg on CVD events, all-cause mortality, kidney disease progression, and rate of age-related decline in cognition and incident dementia. 2 While there were significantly higher rates of some adverse events in the lower BP goal group, there were no differences in all serious adverse events. The absolute differences in these adverse events between randomized groups were relatively 1 The final analyses of the renal outcome data by race/ethnicity from SPRINT will be important because of higher rates of renal failure in AA and Hispanic patients. 4 Although the number of total pre-specified renal events was <30 for participants with CKD at baseline (primary renal outcome), the pre-specified secondary renal outcome (30% reduction in eGFR to < 60 mL/ min/1.73m 2 in participants without CKD at baseline) was more frequent in those randomized to the <120 mm Hg target arm. In addition, acute kidney injury (AKI) or acute kidney failure (AKF) was reported about 70% (P<.001) more frequently in hospital discharge summaries of SPRINT participants treated to the lower SBP target.
The racial breakdown for these renal outcomes is not yet available, and confirmation of the discharge summary reports of AKI/AKF is being formally adjudicated by a blinded end-point committee. The high risk Apo L-1 genotype was present in 10% of SPRINT AA participants. , and fewer AA SPRINT participants were enrolled with an eGFR below the level that defined CKD. 3 The relationship between these outcomes, participant race, and high risk Apo L-1 genotype will be important in defining the risk benefit of the lower SBP target in AAs.
uPcomIng data collectIon and analyses
Collection of the final data on cognition and magnetic resonance imaging (MRI) is scheduled to be completed by summer 2016. SPRINT will have one of the largest clinical trial databases and experience of the use of cognitive testing in AA patients and is well-positioned to assess the effect of the BP intervention on longitudinal changes in cognitive function. During the final 4-9 months of observation, the blood pressure delta between the two arms is likely to be smaller because the active blood pressure intervention was transferred from the SPRINT clinics back to the participant's provid-
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ers. The magnitude of the change in delta and its impact on trial outcomes is unclear at this time.
Projected ImPact of sPrInt
SPRINT should shed new light on strategies to reduce heart failure (HF), one of the most frequent, judicated by a blinded panel. 2 Left ventricular hypertrophy was more common in AA SPRINT participants at baseline, 21% compared with 12% (P<.001). Nearly 60% percent of AAs in SPRINT were between aged 50 to 64 years compared with 32% of non-AAs (P<.0001), an age group as noted above where the disparity by race for incident HF is particularly high. Also as noted above, there was a remarkable consistency of treatment effect in the six pre-specified subgroups for the published outcomes. More detailed analyses of heart failure rates by treatment group are underway, including analyses by preserved ejection fraction, reduced ejection fraction, and subgroup analyses by race and ethnicity.
study lImItatIons
SPRINT will not provide direct information on the effect of the lower SBP target in AA patients with elevated BP and diabetes since the latter were excluded from the trial. Another challenge will be how to implement the lower targets into the clinical environments where many AAs, Hispanics, low SES, and rural individuals receive care. In addition, BPs in SPRINT were much more carefully measured and more consistent with recommended procedures than currently in use in most clinical practices. If the positive findings in SPRINT are to be realized, greater attention to the measurement of blood pressure and to the management of these patients will be required. important and lethal forms of endorgan damage from hypertension. AAs have one of the highest rates of HF not preceded by myocardial infarction and much higher rates of HF at younger ages than Whites. 6 In the Atherosclerosis Risk in Communities surveillance study (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) Black men and women aged 55-64 years had first-time acute decompensated HF event rates that were approximately three times that of White men and women. 7 The <120 mm Hg SBP target in SPRINT produced a 38% reduction in decompensated HF and are among the most potent treatment effects seen in the trial. Heart failure in SPRINT was carefully ad-
